Top 25 Companies in Global Human Vaccines Market (2024–2035): Statistics Report Till 2035 Forecast

Description

According to a research report published by Spherical Insights & Consulting, The Global Human Vaccines Market Size Is Projected To Grow From USD 46.95 Billion In 2024 To USD 112.31 Billion By 2035, At A CAGR Of 8.25 % During The Forecast Period 2024–2035. Future opportunities in the human vaccines market include mRNA innovation, personalized vaccines, expansion in emerging markets, pandemic preparedness, therapeutic vaccines for cancer, and increased government funding with global immunization initiatives.

 

Introduction

The global human vaccines market is driven by the rising burden of infectious diseases and the increasing prioritization of preventive healthcare across both developed and emerging economies. The growing incidence of viral and bacterial infections, including influenza, hepatitis, human papillomavirus (HPV), and pneumococcal diseases, continues to generate substantial demand for routine and targeted immunization programs. Governments worldwide, in collaboration with international organizations such as the World Health Organization and Gavi, the Vaccine Alliance, are expanding national immunization schedules and funding large-scale vaccination initiatives to improve public health outcomes. Advancements in vaccine technologies, particularly the development of mRNA-based platforms, recombinant vaccines, and novel adjuvant systems, have significantly enhanced vaccine efficacy, safety profiles, and manufacturing efficiency. These innovations have accelerated vaccine development timelines and enabled rapid responses to emerging health threats. Additionally, increasing investments in research and development by pharmaceutical companies, coupled with public–private partnerships, are fostering innovation and market expansion. The long-term impact of the COVID-19 pandemic has further strengthened global vaccine infrastructure, increased awareness regarding immunization, and encouraged higher uptake rates. Moreover, the growing focus on adult vaccination and the development of vaccines for chronic and lifestyle-related diseases are broadening the application scope. Collectively, these factors are expected to drive sustained growth in the global human vaccines market over the forecast period.

 

 

July 2025 – The World Health Organization and UNICEF reported that global childhood vaccination coverage held steady, but over 14 million infants remained unvaccinated, underscoring the need for expanded immunization efforts and increased vaccine access, especially in low- and middle-income countries to achieve equitable coverage and support market growth.

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Human Vaccines Market.

 

Human Vaccines Market Size & Statistics

• The Market Size for Human Vaccines Was Estimated to be worth USD 46.95 Billion in 2024.
• The Market is Going to Expand at a CAGR of 8.25 % between 2024 and 2035.
• The Global Human Vaccines Market Size is anticipated to reach USD 112.31 Billion by 2035.
• North America is expected to generate the highest demand during the forecast period in the Human Vaccines Market
• Asia Pacific is expected to grow the fastest during the forecast period in the Human Vaccines Market.

Market Segmentation

Global Human Vaccines Market Size, Share, and COVID-19 Impact Analysis, By Vaccine Type,( Inactivated, Live Attenuated, Subunit, Recombinant and Toxoid), By Application Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines and Influenza Vaccines), By Target Diseases,( Infectious Diseases, Oncological Diseases and Autoimmune Diseases), By Regional (North America, Europe, South America, Asia Pacific, Middle East And Africa) and Global Human Vaccines  Market Insights, Industry Trend, Forecasts to 2025 – 2035.

 

Regional growth and revenue                                  

Asia Pacific is expected to grow at the fastest rate during the forecast period in the Human vaccines market. Asia Pacific is the fastest-growing region due to large population size, rising awareness about preventive healthcare, and increasing government immunization programs. Countries like China and India are expanding vaccine manufacturing capabilities and improving healthcare infrastructure. Supportive policies, growing investments in biotechnology, and rising demand for vaccines against infectious diseases are further accelerating market growth in this region.

 

North America is expected to generate the highest revenue during the forecast period in the Human vaccines market. North America holds the highest revenue share owing to its well-established healthcare infrastructure and high adoption of advanced vaccines. Strong presence of leading pharmaceutical companies, continuous research and development, and early adoption of innovative vaccines such as mRNA technology drive market dominance. Additionally, high vaccination coverage rates and significant healthcare spending further contribute to its leading revenue position.

 

 

Top 10 Trends in the Human Vaccines Market

• mRNA Vaccine Technology
• AI and Machine Learning in Vaccine Development
• Combination and Multivalent Vaccines
• Needle-Free Vaccine Delivery Systems
• Variant-Responsive Vaccine Development
• Growth in Infectious Disease Vaccines
• Expansion of Local Manufacturing
• Government Immunization Programs
• Vaccine Innovation and R&D Investment
• New Indications Beyond Infectious Diseases

 

• mRNA Vaccine Technology

mRNA vaccines have revolutionized the human vaccines market by offering faster development timelines and high efficacy. Unlike traditional vaccines, they use genetic instructions to trigger immune responses without using live pathogens. This technology allows rapid adaptation to new and emerging diseases, as seen during the COVID-19 pandemic. It is now being explored for other diseases like influenza, cancer, and rare genetic disorders, making it one of the most promising innovations in modern vaccine development.

 

• AI and Machine Learning in Vaccine Development

Artificial intelligence and machine learning are significantly improving vaccine research by accelerating antigen discovery and optimizing clinical trials. These technologies analyze large datasets to predict immune responses and identify potential vaccine candidates faster than traditional methods. AI also helps reduce costs and failure rates in development. As a result, pharmaceutical companies are increasingly integrating AI tools to streamline processes and enhance the efficiency and accuracy of vaccine innovation.

 

• Combination and Multivalent Vaccines

Combination and multivalent vaccines protect against multiple diseases or strains with a single injection, improving convenience and vaccination coverage. These vaccines reduce the number of visits required, lower healthcare costs, and enhance patient compliance. They are particularly useful in pediatric and routine immunization programs. By simplifying immunization schedules, they help increase global vaccination rates and are becoming a key focus for manufacturers in the expanding vaccines market.

 

• Needle-Free Vaccine Delivery Systems

Needle-free vaccine delivery systems, such as microneedle patches, nasal sprays, and oral vaccines, are gaining popularity due to their ease of use and reduced pain. These methods improve patient acceptance, especially among children and individuals with needle anxiety. They also minimize risks associated with needle use, such as infections and needle-stick injuries. Additionally, these systems can simplify mass vaccination campaigns and are considered highly effective for improving global vaccine accessibility.

 

• Variant-Responsive Vaccine Development

Variant-responsive vaccines are designed to quickly adapt to evolving pathogens, especially viruses like influenza and SARS-CoV-2. This approach allows manufacturers to update vaccine formulations in response to new strains, ensuring continued effectiveness. Regulatory bodies are also supporting faster approval pathways for updated vaccines. This trend is critical for maintaining long-term protection against rapidly mutating viruses and is shaping the future of vaccine development and pandemic preparedness.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the Human vaccines market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

Top 25 Companies Leading the Human Vaccines Market

1. Pfizer Inc.
2. Merck & Co., Inc.
3. GlaxoSmithKline plc (GSK)
4. Sanofi Pasteur
5. Johnson & Johnson Services, Inc.
6. AstraZeneca plc
7. Moderna, Inc.
8. Novavax, Inc.
9. CSL Limited
10. Serum Institute of India Pvt Ltd
11. Bavarian Nordic
12. Mitsubishi Tanabe Pharma Corporation
13. Daiichi Sankyo Company, Ltd.
14. BioNTech SE
15. Sinovac Biotech Ltd.
16. Sinopharm (China National Biotec Group)
17. Bharat Biotech International Ltd.
18. Biological E. Limited
19. CureVac (and affiliates)
20. Incepta Vaccine
21. Eyam Vaccines & Immunotherapeutics
22. AstriVax Therapeutics
23. Sanaria Inc.
24. Sumaya Biotech
25. GenVec

 

• Pfizer Inc.

Headquarters: New York, USA

Pfizer is a leading global biopharmaceutical company known for its extensive vaccine portfolio and breakthroughs in immunization. With a history of vaccine research that includes contributions to polio and smallpox eradication efforts, Pfizer continues to innovate in both traditional and novel vaccine technologies. Its vaccines target bacterial and viral diseases such as pneumococcal infections and meningococcal disease. Pfizer gained worldwide recognition for developing the first widely authorized mRNA COVID-19 vaccine in partnership with BioNTech, setting new standards for rapid vaccine development and global distribution. The company remains focused on expanding its vaccine pipeline to address emerging infectious diseases and improve public health outcomes worldwide.

 

• Merck & Co., Inc.

Headquarters: Rahway, New Jersey, USA

Merck & Co., also known as MSD outside the U.S. and Canada, is one of the oldest pharmaceutical companies with a strong legacy in vaccines. For over a century, Merck has developed vaccines that have become cornerstones of public health, including vaccines for measles, mumps, rubella, and human papillomavirus (HPV). Its vaccine portfolio also includes pneumococcal conjugate vaccines and BCG for tuberculosis prevention. Merck’s commitment to immunization spans research, development, and global distribution, contributing significantly to reducing the burden of infectious diseases worldwide. The company continues to invest in next-generation vaccines and broadening access through partnerships and public health initiatives.

 

• GlaxoSmithKline plc (GSK)

Headquarters: Brentford, England, UK

GSK is a British multinational pharmaceutical and biotechnology leader with a significant presence in the vaccines market. The company develops and supplies vaccines for a range of infectious diseases, including respiratory syncytial virus (RSV), shingles, meningitis, and influenza. GSK combines strong R&D capabilities with global manufacturing to deliver immunization solutions that protect millions of people annually. Its vaccine portfolio emphasizes both established products and innovative platforms aimed at emerging health threats. Despite facing competitive pressures and evolving market dynamics, GSK continues to pursue strategic growth through enhanced pipeline development and targeted acquisitions, reinforcing its role in global vaccine provision.

 

• Sanofi Pasteur.

Headquarters: Lyon, France

Sanofi Pasteur, the vaccines division of Sanofi, is a major global vaccine manufacturer focused on preventing infectious diseases. Its broad portfolio includes vaccines against influenza, meningococcal meningitis, pertussis, and other childhood and adult immunizations. Sanofi’s immunization efforts are underpinned by robust immunoscience research and innovation, driving advancements in vaccine formulation and delivery. The company’s R&D pipeline is active across numerous clinical-stage projects, reflecting its commitment to addressing unmet medical needs and enhancing global vaccine access. Sanofi Pasteur also collaborates with international health organizations to support vaccination programs, particularly in underserved regions, reinforcing its public health impact.

 

• Johnson & Johnson (Janssen)

Headquarters: Santa Clara, California, USA

Johnson & Johnson, through its Janssen Pharmaceuticals unit, is a significant player in the vaccines market, known for developing innovative vaccine technologies. The company’s vaccine research includes adenovirus-based platforms and proprietary technologies aimed at combating infectious diseases. Its single-shot COVID-19 vaccine marked an important milestone in pandemic response, demonstrating the potential of viral vector vaccines. Janssen’s vaccine pipeline continues to explore solutions for various pathogens, supported by cutting-edge research and global partnerships. As part of Johnson & Johnson’s broader healthcare mission, the vaccines business integrates scientific rigor with efforts to enhance access and equity in immunization worldwide.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Human Vaccines Market.

 

Are you ready to discover more about the Human Vaccines market?

The report provides an in-depth analysis of the leading companies operating in the global Human vaccines market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Company Profiles

1. Pfizer Inc.

• Business Overview
• Company Snapshot
• Products Overview
• Company Market Share Analysis
• Company Coverage Portfolio
• Financial Analysis
• Recent Developments
• Merger and Acquisitions
• SWOT Analysis

1. Merck & Co., Inc.
2. GlaxoSmithKline plc (GSK)
3. Sanofi Pasteur
4. Johnson & Johnson Services, Inc.
5. AstraZeneca plc
6. Moderna, Inc.
7. Novavax, Inc.
8. CSL Limited
9. Others.

 

Conclusion

The human vaccines market is experiencing strong growth driven by technological advancements, increasing global health awareness, and continuous government support for immunization programs. Innovations such as mRNA technology, AI-driven research, and needle-free delivery systems are transforming vaccine development and accessibility. Leading companies like Pfizer, Merck, GSK, Sanofi, and Johnson & Johnson continue to dominate the market through robust R&D pipelines and global reach. At the same time, emerging players and regional manufacturers are strengthening supply chains and improving access in developing regions. With rising demand for preventive healthcare and preparedness against future pandemics, the vaccines market is expected to witness sustained expansion and innovation in the coming years.

 

Our Reports:

https://www.sphericalinsights.com/reports/europe-sparkling-wine-market

https://www.sphericalinsights.com/reports/germany-diy-home-improvement-market

https://www.sphericalinsights.com/reports/germany-employer-and-workplace-drug-testing-market

https://www.sphericalinsights.com/reports/india-alkyl-amine-market

https://www.sphericalinsights.com/reports/india-cctv-market

https://www.sphericalinsights.com/reports/india-ceiling-fan-market

https://www.sphericalinsights.com/reports/india-construction-demolition-waste-recycling-market

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter